We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Renal Expression of Immunomodulators in Diabetic Nephropathy

By LabMedica International staff writers
Posted on 12 Aug 2020
Diabetic nephropathy (DN) is a chronic microvascular complication that affects about 20% to 30% of patients with type 2 diabetes mellitus (T2DM). More...
It is considered the leading cause of end-stage renal failure requiring renal replacement therapy.

Immune and inflammatory mechanisms play important role in the development and progression of DN, which is considered a chronic inflammatory disease. Several cells, such as monocytes, macrophages, and lymphocytes, as well as the immunomodulators chemokines and cytokines, have been implicated in this process.

Medical scientists at the Federal University of Triângulo Mineiro (Uberaba, Brazil) selected 44 native renal biopsies from patients with DN and 23 control cases. The diagnosis of DN was performed with three samples used for light microscopy (LM), direct immunofluorescence (IF) and transmission electron microscopy (TEM). For LM, 2-μm paraffin sections were stained with hematoxylin and eosin (H&E), Sirius red, methenamine silver, and Masson’s trichrome. LM was used to analyze morphological changes and interstitial inflammation.

Immunohistochemistry was performed manually on slides containing paraffin-embedded tissue sections using the Novolink Polymer Detection System Kit, a non-biotin polymer system (Leica Biosystems, Nussloch, Germany; www.leicabiosystems.com). In situ expression of eotaxin, macrophage inflammatory protein-1α (MIP-1α), interleukin-8 (IL-8), IL-4, IL-10, tumor necrosis factor-α (TNF-α ), tumor necrosis factor receptor-1 (TNFR1), IL-1β, and IL-6 were evaluated by immunohistochemistry. Immunostained cells showing an intense brownish staining were marked by the observer using the interactive AxionCam ICc 5 image analysis system (Carl Zeiss Microscopy GmbH, Jena, Germany; www.zeiss.de).

The team reported that the DN group showed a significant increase in IL-6, IL-1β, IL-4 and eotaxin expression, and a decrease in TNFR1 and IL-8 expression compared to the control group. However, there were no significant differences in IL-10, TNF-α, and MIP-1α expression among groups. With interstitial inflammation, there was a significant increase in IL-6 in scores 0 and 1 compared to score 2 , in IL-10 in score 2 compared to score 0, and in eotaxin in score 2 compared to scores 0 and 1, whereas IL-8 and MIP-1α showed no significant differences. There was a tendency for negative correlation between eotaxin and estimated glomerular filtration rate (eGFR).

The authors concluded that that in situ expression of cytokines and chemokines, including IL-6, IL-1β, IL-4 and eotaxin, is increased in patients with DN. It was observed that, possibly, eotaxin may have an important role in progression of interstitial inflammation in DN and in the decrease of eGFR of these patients. The study was published on July 28, 2020 in the journal BMC Nephrology.


Related Links:

Federal University of Triângulo Mineiro
Leica Biosystems
Carl Zeiss Microscopy

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.